

CERTIFICATE

Consent for Audio Visual Recording of Informed Consent Process

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Translations done from English to Hindi is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Translation from English to Hindi

Date of Translation: 21-Apr-2026

DONE BY

Name of Translator: Ms. Ambika Rawat

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Himanshu Pathak

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

India AV/Audio ICF Version Date: 21 Jul 2025, Version Number: 1.0

Site AV/Audio ICF Version Date: 08 April 2026, Version Number: 1.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center



CERTIFICATE

Consent for Audio Visual Recording of Informed Consent Process

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Back Translations done from Hindi to English is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Back Translation from Hindi to English

Date of Back Translation: 21-Apr-2026

DONE BY

Name of Translator: Mr. Manpreet Singh

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Nishanth N

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

India AV/Audio ICF Version Date: 21 Jul 2025, Version Number: 1.0

Site AV/Audio ICF Version Date: 08 April 2026, Version Number: 1.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center



CERTIFICATE

INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Translations done from English to Hindi is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Translation from English to Hindi

Date of Translation: 21-Apr-2026

DONE BY

Name of Translator: Ms. Ambika Rawat

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Himanshu Pathak

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Clinical ICF Version Date:18 Feb 2026, Version Number: 1.0

Site Clinical ICF Version Date:08 Apr 2026, Version Number: 1.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center



CERTIFICATE

INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Back Translations done from Hindi to English is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Back Translation from Hindi to English

Date of Back Translation: 21-Apr-2026

DONE BY

Name of Translator: Mr. Manpreet Singh

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Nishanth N

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Clinical ICF Version Date: 18 Feb 2026, Version Number: 1.0

Site Clinical ICF Version Date: 08 Apr 2026, Version Number: 1.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center



CERTIFICATE

WITHDRAWAL INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlogy-5)

This is to certify that the Translations done from English to Hindi is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Translation from English to Hindi

Date of Translation: 21-Apr-2026

DONE BY

Name of Translator: Ms. Ambika Rawat

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Himanshu Pathak

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Withdrawal Informed Consent Form Version Date: 17 Feb 2026 Version No.:1.0

Site Withdrawal Informed Consent Form Version Date: 08 April 2026 Version No.:1.1.0

PI: Dr. Jeevan Kumar; PI: Tata Medical Center



CERTIFICATE

WITHDRAWAL INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlogy-5)

This is to certify that the Back Translations done from Hindi to English is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Back Translation from Hindi to English

Date of Back Translation: 21-Apr-2026

DONE BY

Name of Translator: Mr. Manpreet Singh

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Nishanth N

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Withdrawal Informed Consent Form Version Date: 17 Feb 2026 Version No.:1.0

Site Withdrawal Informed Consent Form Version Date: 08 April 2026 Version No.:1.1.0

PI: Dr. Jeevan Kumar; PI: Tata Medical Center



CERTIFICATE

PREGNANCY IN CLINICAL STUDY INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Translations done from English to Hindi is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Translation from English to Hindi

Date of Translation: 21-Apr-2026

DONE BY

Name of Translator: Ms. Ambika Rawat

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Himanshu Pathak

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Pregnancy in Clinical Study ICF Version Date:17 Feb 2026, Version Number:1.0

Site Pregnancy in Clinical Study ICF Version Date:14 Apr 2026, Version Number:2.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center, Kolkata



CERTIFICATE

PREGNANCY IN CLINICAL STUDY INFORMED CONSENT FORM

Study Title: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide (TRIlology-5)

This is to certify that the Back Translations done from Hindi to English is of good quality, accurate and to the best of our knowledge, but subject to the final approval of the translated documents by the Client and including Customization for the following doctors: Dr. Jeevan Kumar

Protocol Number: 79635322MMY3002

Back Translation from Hindi to English

Date of Back Translation: 21-Apr-2026

DONE BY

Name of Translator: Mr. Manpreet Singh

Quality Check (QC) review for accuracy and completeness has been carried out for this document on 21-Apr-2026

By: Mr. Nishanth N

Esther.D

Esther.D (Apr 21, 2026 21:13:48 GMT+5.5)

Authorized Signature & Date:

Name of Project Manager: Ms. Esther D

Master Pregnancy in Clinical Study ICF Version Date:17 Feb 2026, Version Number:1.0

Site Pregnancy in Clinical Study ICF Version Date:14 Apr 2026, Version Number:2.1.0

PI: Dr. Jeevan Kumar; Site: Tata Medical Center, Kolkata

